Peak Asset Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,755 shares of the medical research company's stock, valued at approximately $2,384,000.
A number of other large investors also recently modified their holdings of the stock. Elyxium Wealth LLC raised its position in Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after purchasing an additional 20 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its position in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares during the period. Canandaigua National Trust Co of Florida boosted its stake in shares of Thermo Fisher Scientific by 3.0% in the 4th quarter. Canandaigua National Trust Co of Florida now owns 765 shares of the medical research company's stock valued at $443,000 after purchasing an additional 22 shares during the last quarter. Finally, Princeton Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 2.4% during the fourth quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company's stock worth $534,000 after buying an additional 22 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 73,493 shares of company stock valued at $43,950,381 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Piper Sandler upped their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. Jefferies Financial Group reissued a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, HSBC cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price target for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $619.41.
View Our Latest Research Report on TMO
Thermo Fisher Scientific Trading Down 0.1%
Shares of NYSE:TMO opened at $628.69 on Tuesday. The firm has a market cap of $232.46 billion, a price-to-earnings ratio of 33.82, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company's fifty day simple moving average is $545.64 and its 200 day simple moving average is $509.60. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 EPS. The company's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is presently 10.11%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
